Benzinga | Nov 6, 2020 11:43AM EST

Canaccord Genuity Maintains Buy on Sage Therapeutics, Raises Price Target to $135

Canaccord Genuity maintains Sage Therapeutics (NASDAQ:SAGE) with a Buy and raises the price target from $82 to $135.